口腔医学研究

口腔医学研究 ›› 2019, Vol. 35 ›› Issue (7): 666-670.DOI: 10.13701/j.cnki.kqyxyj.2019.07.012

• 口腔黏膜学研究 • 上一篇    下一篇

Smads蛋白在口腔慢性移植物抗宿主病患者血浆中的表达

周雨曦1,2,3,4,5, 陶人川1*, 江巧芝1   

  1. 1. 广西医科大学附属口腔医院牙周黏膜科 广西 南宁 530021;
    2. 广西口腔颌面修复与重建研究自治区级重点实验室 广西 南宁 530021;
    3. 广西颅颌面畸形临床医学研究中心 广西 南宁 530021;
    4. 颌面外科疾病诊治研究重点实验室 广西 南宁 530021;
    5. 广西艾滋病防治研究重点实验室 广西 南宁 530021
  • 收稿日期:2018-11-19 出版日期:2019-07-25 发布日期:2019-07-24
  • 通讯作者: 陶人川,E-mail:dr.taorc@foxmail.com
  • 作者简介:周雨曦(1993~ )女,湖南益阳人,硕士在读,主要从事口腔牙周黏膜学研究
  • 基金资助:
    国家自然科学基金(编号:81771073) 广西自然科学基金(编号:2015GXNSFDA139018、 2014GXNSFAA118149)

Expression of Smads Protein in Plasma of Oral Chronic Graft versus Host Disease

ZHOU Yuxi1,2,3,4,5, TAO Renchuan1*, JIANG Qiaozhi1   

  1. 1. Department of Periodontics and Oral Medicine, Stomatological Hospital, Guangxi Medical University, Nanning 530021, China;
    2. Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction, Nanning 530021,China;
    3. Guangxi Clinical Medical Research Center for Craniofacial Deformity, Nanning 530021,China;
    4. Guangxi Key Laboratory of Oral and Maxillofacial Surgery Diseases Treatment, Nanning 530021,China;
    5. Guangxi Key Laboratory of AIDS Prevention and Treatment, Nanning 530021,China.
  • Received:2018-11-19 Online:2019-07-25 Published:2019-07-24

PDF (PC)

137

摘要： 目的:探讨Smad2、3、4、7蛋白在异基因造血干细胞移植后口腔慢性移植物抗宿主病(chronic graft versus host disease,cGVHD)患者血浆中的表达水平及意义。方法:选取异基因造血干细胞移植后确诊为口腔cGVHD的患者18人纳入口腔cGVHD组,异基因造血干细胞移植后没有出现口腔cGVHD的患者18人为无口腔cGVHD组,对照组纳入健康者18人。收集3组血液,通过酶联免疫吸附检测法检测血浆中Smad2、Smad3、Smad4、Smad7蛋白的表达水平。结果:口腔cGVHD组患者血浆中Smad2(78.00±13.53) ng/L、Smad4(484.71±90.86) ng/L蛋白含量均高于对照组(P<0.05),Smad3蛋白表达(95.15±37.32) ng/L低于对照组(P<0.05),Smad7蛋白含量表达无明显差异(P>0.05)。而口腔cGVHD组与无口腔cGVHD组比较,口腔cGVHD组Smad3蛋白表达降低(P<0.05),Smad2和Smad7蛋白表达升高(P<0.05)。结论:血浆中Smads蛋白的表达异常可能参与口腔cGVHD的发生

关键词: 异基因造血干细胞移植, 口腔慢性移植物抗宿主病, Smads

Abstract: Objective: To investigate the expression and significance of Smad2, 3, 4, and 7 in plasma of patients with oral chronic graft versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation. Methods: 18 patients with oral cGVHD after allogeneic hematopoietic stem cell transplantation were selected as oral cGVHD group and recorded with the oral characterization score and VAS. 18 patients without oral cGVHD after transplantation were recruited as no-oral cGVHD group, and 18 healthy volunteers were selected as healthy controls. Three groups of blood were collected and the expressions of protein levels of Smad2, Smad3, Smad4, and Smad7 in plasma were detected by ELISA. Results: The protein levels of Smad2 [(78.00±13.53)ng/L] and Smad4 [(484.71±90.86)ng/L] in plasma of the oral cGVHD group were higher than those of the healthy controls (P<0.05), and the expression of Smad3 [(95.15±37.32)ng/L] protein was lower than that of the healthy controls (P<0.05). There was no significant difference in the expression of Smad7 protein in these two groups (P>0.05) Compared with non-oral cGVHD group, oral cGVHD group had lower expression of Smad3 protein and higher expression of Smad2 and Smad7 protein (P<0.05). Conclusion: Abnormal expression of Smads protein in plasma may be involved in the occurrence of oral cGVHD

Key words: allogeneic hematopoietic stem cell transplantation , oral graft versus host disease , Smads